Injectable hydrogel encapsulating siMMP13 with anti-ROS and anti-apoptotic functions for osteoarthritis treatment

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Molecular Biology

Background:

• Osteoarthritis (OA) is a degenerative joint disease driven by cartilage breakdown, oxidative stress, and chondrocyte apoptosis.
• RNA interference (RNAi) offers targeted gene silencing for diseases like OA, with MMP13 inhibition being a key strategy.
• Current OA treatments lack efficacy in halting disease progression.

Purpose of the Study:

• To develop an injectable hydrogel for sustained delivery of siMMP13 (small interfering RNA targeting MMP13) for OA treatment.
• To evaluate the therapeutic efficacy of the siMMP13-loaded hydrogel in a mouse model of OA.
• To assess the hydrogel's impact on cartilage degradation, oxidative stress, and chondrocyte apoptosis.

Main Methods:

• Development of an injectable hydrogel encapsulating liposome-siMMP13 and NG-Monomethyl-L-arginine Acetate (L-NMMA).
• Administration of the hydrogel in a destabilization of the medial meniscus (DMM) mouse model of OA.
• Histological analysis of cartilage structure, proteoglycan content, oxidative stress markers, and apoptosis in chondrocytes.

Main Results:

• The composite hydrogel demonstrated significant inhibition of cartilage matrix degradation in DMM mice.
• Histological evaluation revealed preserved cartilage structure and reduced proteoglycan loss.
• The treatment effectively suppressed intracellular reactive oxygen species (ROS) and attenuated chondrocyte apoptosis.

Conclusions:

• The injectable hydrogel loaded with siMMP13 exhibits promising therapeutic potential for osteoarthritis.
• The hydrogel's combined anti-ROS and anti-apoptotic properties contribute to its efficacy in preserving cartilage.
• This approach offers a novel strategy for OA management by targeting key pathological pathways.